These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 20859662)

  • 1. Solubility advantage of amorphous pharmaceuticals: II. Application of quantitative thermodynamic relationships for prediction of solubility enhancement in structurally diverse insoluble pharmaceuticals.
    Murdande SB; Pikal MJ; Shanker RM; Bogner RH
    Pharm Res; 2010 Dec; 27(12):2704-14. PubMed ID: 20859662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis.
    Murdande SB; Pikal MJ; Shanker RM; Bogner RH
    J Pharm Sci; 2010 Mar; 99(3):1254-64. PubMed ID: 19697391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What is the true solubility advantage for amorphous pharmaceuticals?
    Hancock BC; Parks M
    Pharm Res; 2000 Apr; 17(4):397-404. PubMed ID: 10870982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting the solubility enhancement of amorphous drugs and related phenomena using basic thermodynamic principles and semi-empirical kinetic models.
    Skrdla PJ; Floyd PD; Dell'Orco PC
    Int J Pharm; 2019 Aug; 567():118465. PubMed ID: 31279056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of drug-polymer miscibility and solubility in amorphous solid dispersions using experimentally determined interaction parameters.
    Marsac PJ; Li T; Taylor LS
    Pharm Res; 2009 Jan; 26(1):139-51. PubMed ID: 18779927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicted amorphous solubility and dissolution rate advantages following moisture sorption: Case studies of indomethacin and felodipine.
    Skrdla PJ; Floyd PD; Dell'Orco PC
    Int J Pharm; 2019 Jan; 555():100-108. PubMed ID: 30448307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Accuracy of Amorphous Solubility Advantage Calculation by Comparison with Experimental Solubility Measurement in Buffer and Biorelevant Media.
    Zhang W; Haser A; Hou HH; Nagapudi K
    Mol Pharm; 2018 Apr; 15(4):1714-1723. PubMed ID: 29522344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aqueous solubility of crystalline and amorphous drugs: Challenges in measurement.
    Murdande SB; Pikal MJ; Shanker RM; Bogner RH
    Pharm Dev Technol; 2011 Jun; 16(3):187-200. PubMed ID: 20429826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solubility advantage of amorphous pharmaceuticals, part 3: Is maximum solubility advantage experimentally attainable and sustainable?
    Murdande SB; Pikal MJ; Shanker RM; Bogner RH
    J Pharm Sci; 2011 Oct; 100(10):4349-56. PubMed ID: 21630280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly supersaturated solutions of amorphous drugs approaching predictions from configurational thermodynamic properties.
    Matteucci ME; Miller MA; Williams RO; Johnston KP
    J Phys Chem B; 2008 Dec; 112(51):16675-81. PubMed ID: 19367943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuances in the Calculation of Amorphous Solubility Enhancement Ratio.
    Manchanda A; Kleppe MS; Bogner RH
    J Pharm Sci; 2019 Nov; 108(11):3560-3574. PubMed ID: 31271772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
    Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physical stability and solubility advantage from amorphous celecoxib: the role of thermodynamic quantities and molecular mobility.
    Gupta P; Chawla G; Bansal AK
    Mol Pharm; 2004; 1(6):406-13. PubMed ID: 16028352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility.
    Marsac PJ; Shamblin SL; Taylor LS
    Pharm Res; 2006 Oct; 23(10):2417-26. PubMed ID: 16933098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting the Solubility Advantage of Amorphous Pharmaceuticals: A Novel Thermodynamic Approach.
    Paus R; Ji Y; Vahle L; Sadowski G
    Mol Pharm; 2015 Aug; 12(8):2823-33. PubMed ID: 26107071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical Estimation of Amorphous Solubility Enhancement Using Thermoanalytical Data: Determination of the Amorphous/Crystalline Solubility Ratio for Pure Indomethacin and Felodipine.
    Skrdla PJ; Floyd PD; Dell'orco PC
    J Pharm Sci; 2016 Sep; 105(9):2625-2630. PubMed ID: 27372548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amorphous and Crystalline Particulates: Challenges and Perspectives in Drug Delivery.
    Al-Obaidi H; Majumder M; Bari F
    Curr Pharm Des; 2017; 23(3):350-361. PubMed ID: 27829335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating the maximal solubility advantage of drug salts.
    Skrdla PJ
    Int J Pharm; 2021 Feb; 595():120228. PubMed ID: 33484924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of hydrate forms of paroxetine HCl from the amorphous state: an evaluation of thermodynamic and experimental predictive approaches.
    Pina MF; Pinto JF; Sousa JJ; Craig DQ; Zhao M
    Int J Pharm; 2015 Mar; 481(1-2):114-24. PubMed ID: 25592956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solubility Advantage (and Disadvantage) of Pharmaceutical Amorphous Solid Dispersions.
    Huang S; Mao C; Williams RO; Yang CY
    J Pharm Sci; 2016 Dec; 105(12):3549-3561. PubMed ID: 27692620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.